Survival Analysis of Brain Metastases Treatments
Author Information
Author(s): Elaimy Ameer L, Mackay Alexander R, Lamoreaux Wayne T, Fairbanks Robert K, Demakas John J, Cooke Barton S, Peressini Benjamin J, Holbrook John T, Lee Christopher M
Primary Institution: Cancer Care Northwest
Hypothesis
What factors influence the survival of patients with brain metastases treated with different modalities?
Conclusion
Patients treated with a combined modality approach, particularly SRS alone or resection with SRS, showed better survival outcomes compared to those treated with WBRT alone.
Supporting Evidence
- Patients treated with SRS alone had a median survival of 9.4 months.
- Patients treated with WBRT alone had a median survival of 4.3 months.
- Survival favored patients <65 years of age with a median survival of 11 months.
- ECOG-PS class 0 patients had a median survival of 22 months.
Takeaway
This study looked at how different treatments for brain cancer affect how long patients live. It found that some treatments work better than others.
Methodology
The study analyzed treatment regimens, age, ECOG-PS, primary tumor histology, number of brain metastases, and total volume of brain metastases using statistical methods including Kaplan-Meier survival curves and Cox proportional hazard models.
Limitations
ECOG-PS class was not recorded for 162 patients and total tumor volume was not recorded for 151 patients.
Participant Demographics
Median age was 60 years, with a range from 29 to 86 years; non-small-cell lung cancer was the most common primary tumor histology.
Statistical Information
P-Value
p<0.001
Confidence Interval
95% CI, 1.37-2.73
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website